Corrigendum to “HDR Brachytherapy in the Management of High-Risk Prostate Cancer”

In the article titled “HDR Brachytherapy in the Management of High-Risk Prostate Cancer” [1], there was an error in Table 2, which should be corrected as follows: For Hoskin et al. [32], the dose should read 35.75 Gy in 13 fractions EBRT, not 55 Gy in 20 fractions EBRT.

Saved in:
Bibliographic Details
Published in:Advances in urology 2016-01, Vol.2016 (2016), p.1-1
Main Authors: Masson, Susan, Bahl, Amit, Persad, Raj
Format: Article
Language:English
Subjects:
Corrigendum
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c4096-116cb78d41c45f99ae17e1594be2e794d44b77e1b20be3601f1bbfdd7f02f35d3
container_end_page 1
container_issue 2016
container_start_page 1
container_title Advances in urology
container_volume 2016
creator Masson, Susan
Bahl, Amit
Persad, Raj
description In the article titled “HDR Brachytherapy in the Management of High-Risk Prostate Cancer” [1], there was an error in Table 2, which should be corrected as follows: For Hoskin et al. [32], the dose should read 35.75 Gy in 13 fractions EBRT, not 55 Gy in 20 fractions EBRT.
doi_str_mv 10.1155/2016/6345816
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_a78b9b9326dd4b9682b1cb8a5c82cd14</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A491087067</galeid><doaj_id>oai_doaj_org_article_a78b9b9326dd4b9682b1cb8a5c82cd14</doaj_id><sourcerecordid>A491087067</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4096-116cb78d41c45f99ae17e1594be2e794d44b77e1b20be3601f1bbfdd7f02f35d3</originalsourceid><addsrcrecordid>eNqNkkuLFDEQgBtR3IfePEuDIILObtKdzuMirONjFlaUxT2HPKq7s3Yns-melbntD9E_t7_EjDMOM-BBckhR-fKRqlSWPcPoBOOqOi0Qpqe0JBXH9EF2iClnE1oy9nAbU3GQHQ3DNUIUc8YeZwcFR6QoRHmYXU1DjK4Bbxd9Pob8_u7n7P1l_i4q0y7HFqKaL3Pn8xTmn5VXDfTgxzzU-cw17eTSDd_zrzEMoxohnypvIN7f_XqSPapVN8DTzX6cXX388G06m1x8-XQ-PbuYGIIEnWBMjWbcEmxIVQuhADPAlSAaCmCCWEI0SxldIA0lRbjGWtfWshoVdVnZ8jg7X3ttUNdyHl2v4lIG5eSfRIiNVHF0pgOpGNdCi7Kg1hItKC80NpqryvDCWEyS6-3aNV_oHqxJZUbV7Un3T7xrZRNuZYVLmpqcBK82ghhuFjCMsneDga5THsJikJhXhKOSlyihL9Zoo9LTnK9DMpoVLs-IwIgzRFmiTv5BpWWhdyZ4qF3K7114uXOhBdWN7RC6xeiCH_bBN2vQpK8bItTbMjGSq6mSq6mSm6lK-PPd1mzhv2OUgNdroHXeqh_uP3WQGKjVDi0oq1D5G4Or3co</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1854803830</pqid></control><display><type>article</type><title>Corrigendum to “HDR Brachytherapy in the Management of High-Risk Prostate Cancer”</title><source>Wiley-Blackwell Open Access Collection</source><source>PubMed Central</source><creator>Masson, Susan ; Bahl, Amit ; Persad, Raj</creator><creatorcontrib>Masson, Susan ; Bahl, Amit ; Persad, Raj</creatorcontrib><description>In the article titled “HDR Brachytherapy in the Management of High-Risk Prostate Cancer” [1], there was an error in Table 2, which should be corrected as follows: For Hoskin et al. [32], the dose should read 35.75 Gy in 13 fractions EBRT, not 55 Gy in 20 fractions EBRT.</description><identifier>ISSN: 1687-6369</identifier><identifier>EISSN: 1687-6377</identifier><identifier>DOI: 10.1155/2016/6345816</identifier><identifier>PMID: 28042293</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Corrigendum</subject><ispartof>Advances in urology, 2016-01, Vol.2016 (2016), p.1-1</ispartof><rights>Copyright © 2016 Susan Masson et al.</rights><rights>COPYRIGHT 2016 John Wiley &amp; Sons, Inc.</rights><rights>Copyright © 2016 Susan Masson et al. 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4096-116cb78d41c45f99ae17e1594be2e794d44b77e1b20be3601f1bbfdd7f02f35d3</cites><orcidid>0000-0001-7747-0412</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5136636/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5136636/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28042293$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Masson, Susan</creatorcontrib><creatorcontrib>Bahl, Amit</creatorcontrib><creatorcontrib>Persad, Raj</creatorcontrib><title>Corrigendum to “HDR Brachytherapy in the Management of High-Risk Prostate Cancer”</title><title>Advances in urology</title><addtitle>Adv Urol</addtitle><description>In the article titled “HDR Brachytherapy in the Management of High-Risk Prostate Cancer” [1], there was an error in Table 2, which should be corrected as follows: For Hoskin et al. [32], the dose should read 35.75 Gy in 13 fractions EBRT, not 55 Gy in 20 fractions EBRT.</description><subject>Corrigendum</subject><issn>1687-6369</issn><issn>1687-6377</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNqNkkuLFDEQgBtR3IfePEuDIILObtKdzuMirONjFlaUxT2HPKq7s3Yns-melbntD9E_t7_EjDMOM-BBckhR-fKRqlSWPcPoBOOqOi0Qpqe0JBXH9EF2iClnE1oy9nAbU3GQHQ3DNUIUc8YeZwcFR6QoRHmYXU1DjK4Bbxd9Pob8_u7n7P1l_i4q0y7HFqKaL3Pn8xTmn5VXDfTgxzzU-cw17eTSDd_zrzEMoxohnypvIN7f_XqSPapVN8DTzX6cXX388G06m1x8-XQ-PbuYGIIEnWBMjWbcEmxIVQuhADPAlSAaCmCCWEI0SxldIA0lRbjGWtfWshoVdVnZ8jg7X3ttUNdyHl2v4lIG5eSfRIiNVHF0pgOpGNdCi7Kg1hItKC80NpqryvDCWEyS6-3aNV_oHqxJZUbV7Un3T7xrZRNuZYVLmpqcBK82ghhuFjCMsneDga5THsJikJhXhKOSlyihL9Zoo9LTnK9DMpoVLs-IwIgzRFmiTv5BpWWhdyZ4qF3K7114uXOhBdWN7RC6xeiCH_bBN2vQpK8bItTbMjGSq6mSq6mSm6lK-PPd1mzhv2OUgNdroHXeqh_uP3WQGKjVDi0oq1D5G4Or3co</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Masson, Susan</creator><creator>Bahl, Amit</creator><creator>Persad, Raj</creator><general>Hindawi Publishing Corporation</general><general>John Wiley &amp; Sons, Inc</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-7747-0412</orcidid></search><sort><creationdate>20160101</creationdate><title>Corrigendum to “HDR Brachytherapy in the Management of High-Risk Prostate Cancer”</title><author>Masson, Susan ; Bahl, Amit ; Persad, Raj</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4096-116cb78d41c45f99ae17e1594be2e794d44b77e1b20be3601f1bbfdd7f02f35d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Corrigendum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Masson, Susan</creatorcontrib><creatorcontrib>Bahl, Amit</creatorcontrib><creatorcontrib>Persad, Raj</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Advances in urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Masson, Susan</au><au>Bahl, Amit</au><au>Persad, Raj</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Corrigendum to “HDR Brachytherapy in the Management of High-Risk Prostate Cancer”</atitle><jtitle>Advances in urology</jtitle><addtitle>Adv Urol</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>2016</volume><issue>2016</issue><spage>1</spage><epage>1</epage><pages>1-1</pages><issn>1687-6369</issn><eissn>1687-6377</eissn><abstract>In the article titled “HDR Brachytherapy in the Management of High-Risk Prostate Cancer” [1], there was an error in Table 2, which should be corrected as follows: For Hoskin et al. [32], the dose should read 35.75 Gy in 13 fractions EBRT, not 55 Gy in 20 fractions EBRT.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>28042293</pmid><doi>10.1155/2016/6345816</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-7747-0412</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1687-6369
ispartof Advances in urology, 2016-01, Vol.2016 (2016), p.1-1
issn 1687-6369
1687-6377
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_a78b9b9326dd4b9682b1cb8a5c82cd14
source Wiley-Blackwell Open Access Collection; PubMed Central
subjects Corrigendum
title Corrigendum to “HDR Brachytherapy in the Management of High-Risk Prostate Cancer”
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T13%3A56%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Corrigendum%20to%20%E2%80%9CHDR%20Brachytherapy%20in%20the%20Management%20of%20High-Risk%20Prostate%20Cancer%E2%80%9D&rft.jtitle=Advances%20in%20urology&rft.au=Masson,%20Susan&rft.date=2016-01-01&rft.volume=2016&rft.issue=2016&rft.spage=1&rft.epage=1&rft.pages=1-1&rft.issn=1687-6369&rft.eissn=1687-6377&rft_id=info:doi/10.1155/2016/6345816&rft_dat=%3Cgale_doaj_%3EA491087067%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4096-116cb78d41c45f99ae17e1594be2e794d44b77e1b20be3601f1bbfdd7f02f35d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1854803830&rft_id=info:pmid/28042293&rft_galeid=A491087067&rfr_iscdi=true